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Over the past decades, the search for clues to the understand-
ing of renal function and disease has led to the ongoing
development of innovative laboratory techniques to approach
these questions on the single nephron level, Development of
renal micropuncture techniques has allowed assessment of the
single nephron glomerular filtration (SNGFR) and its determi-
nants, as well as of tubular transport characteristics. The
history and techniques of micropuncture study have recently
been reviewed [1]. This brief review will focus on three specific
aspects of how single nephron studies have been used to
provide insights into human glomerular function: explication of
hemodynamic patterns of disease; definition of effects of hor-
monal mediators of glomerular function, allowing correlation
with hemodynamic disease patterns; and identification of mech-
anisms contributing to efficacy of therapeutic interventions.
Hemodynamic patterns in renal disease
In clinical practice, nephrologists are relatively limited in
ability to define hemodynamic patterns of disease. Clinical
examination of renal function usually consists of measurement
of glomerular filtration rate (GFR) by the less than perfectly
accurate creatinine clearance method [2]. Clinical investiga-
tions can utilize better techniques: more accurate measurement
of GFR using inulin or radioisotopic methods; measurement of
renal plasma flow using para-aminohippurate or isotopic meth-
ods (though usually not corrected for renal extraction); and
more sophisticated methods involving dextran modelling [2, 3].
Determination of whole kidney GFR can only reveal whether
total filtration function is increased, normal, or decreased; this
measurement sheds little light on hemodynamic patterns at the
microcirculatory level. Development of a number of different
animal models of renal disease, chosen to mimic a variety of
human clinical diseases, has allowed elucidation of single
nephron hemodynamics using micropuncture techniques in
laboratory animals (usually the rat). These studies generally
involve measurement of GFR at the whole kidney and single
nephron level. The major determinants of SNGFR [the glomer-
ular capillary plasma flow rate, QA; the glomerular capillary
hydraulic pressure (Gc) and the transcapillary hydraulic pres-
sure gradient (AP); plasma colloid oncotic pressure; and the
ultrafiltration coefficient (K)I are determined. These measure-
ments, together with measurements of mean arterial pressure
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and postglomerular capillary pressure, allow calculation of the
glomerular afferent (RA) and efferent (Re) arteriolar resistances
[41.
Such studies in diverse disease models have established that
within the three categories of whole kidney GFR (high, normal,
or low), substantial variations in the hemodynamic determi-
nants of SNGFR may be found. Representative examples of
some prominent patterns of disease are depicted in Table 1
[5—14], and are briefly described here. Elevation of whole
kidney GFR ("hyperfiltration") may result from substantial
increases in both capillary perfusion and the glomerular capil-
lary hydraulic pressure—a hemodynamic pattern which is as-
sociated with progressive injury in a number of disease states.
However, hyperfiltration may also result from increased renal
perfusion without glomerular capillary hypertension; this be-
nign condition characterizes normal pregnancy [9] and is not
usually associated with progressive renal disease. Findings of a
normal GFR may reflect normal renal function, or compensa-
tory adaptations leading to hyperfunction in a decreased num-
ber of nephrons. In some cases, as in progressive renal disease
occurring long after acute renal failure [9], the GFR may be
normal, and yet intrarenal adaptations (increased P0c and
decreased K) are found. When GFR is reduced, the cause may
be a primary reduction in the ultrafiltration coefficient (due to
limitation of hydraulic permeability and/or the surface area
available for filtration), as is the case in many forms of exper-
imental glomerulonephritis [9, 13]. Alternatively, a low GFR
may represent inability of a reduced number of hyperfiltering
functioning nephrons to maintain GFR (despite various intra-
renal adaptations), or a primary decrease in renal perfusion, as
occurs in severe renal artery stenosis [14].
Major patterns in experimental renal disease
Though many different hemodynamic patterns may be found,
micropuncture studies have revealed that two major maladap-
tations are particularly prominent, and are most frequently
found in studies of experimental renal disease.
Afferent arteriolar vasodilation
A number of experimental models have in common a primary
defect in the afferent arteriole, such that afferent arteriolar
resistance is solely reduced, or reduced disproportionately to a
smaller decrement in efferent arteriolar resistance. As the
ability of the afferent arteriole to dilate or constrict is a critical
component of the kidney's defense against changes in renal
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perfusion pressure, this persistent afferent arteriolar vasodila-
tion leads to defective autoregulation. Failure of the afferent
arteriole to constrict in the setting of elevated blood pressure
can lead to enhanced transmission of systemic pressures into
the glomerular capillary network, and glomerular capillary
hypertension. Indeed, persistent afferent vasodilation can
sometimes lead to glomerular hypertension despite a systemic
blood pressure which is normal.
Afferent arteriolar vasodilation is found in a number of
experimental models, representing important clinical diseases.
A few examples of these include diabetes [5—7], reduced renal
mass [15], certain spontaneous models including the Dahi
salt-sensitive rat [16], and normal aging [10]. The importance of
afferent arteriolar vasodilation in protecting the glomerulus
against local glomerular capillary hypertension has been ele-
gantly demonstrated in many studies. For example, Hostetter et
al [15] evaluated single nephron function in rats subjected to
severe reduction in renal mass. In this model, both afferent and
efferent arteriolar resistances are reduced, as compared to
values in sham-operated animals (Fig. 1). Since the reduction in
afferent resistance exceeds that in RE,the glomerular capillary
hydraulic pressure rises. When afferent arteriolar tone is re-
turned to normal (in this case, by dietary protein restriction)
glomerular capillary pressure is also normalized [15].
A similar pathogenetic role for afferent vasodilation, and its
long-term consequences, was demonstrated by Dworkin and
Feiner [11] in a study of the Spontaneously Hypertensive Rat
(SHR). This model is characterized by very high systemic blood
pressures; however, afferent arteriolar vasoconstriction pre-
vents transmission of systemic pressures into the glomerular
capillary network, Gc remains normal, and development of
proteinuria (Fig. 2) and glomerular sclerosis is modest. Re-
moval of one kidney in the SHR results in lowering of RA in the
remaining kidney, allowing transmission of systemic hyperten-
sion and elevation of GC This hemodynamic alteration is
associated with a sharp increase in proteinuria (Fig. 2), and
acceleration of glomerular sclerosis. When the uninephrecto-
mized SHR is fed a low protein diet, the protective afferent
arteriolar vasoconstriction is restored, GC is maintained at
normal levels, and proteinuria and glomerular structural injury
are prevented [11].
It seems likely that afferent arteriolar vasodilation is present
in some of the most prominent clinical renal diseases, including
Fig. 1. Effects of subtotal nephrectomy (NX) and low protein diet
(LPD) on afferent (RA) and efferent (RE) arteriolar resistances, and
glomerular capilla,y pressure (PGC). In untreated rats, afferent arterio-
lar vasodilation leads to glomerular capillary hypertension; both are
reversedwith dietary protein restriction. * P< 0.05 vs. Sham. Adapted
from data in Ref. 15 with permission.
diabetes, late progressive renal disease after various acute
insults, perhaps during normal aging, and in patients with a
solitary kidney due to uninephrectomy or renal transplantation.
Reduction in the ultrafiltration coefficient
A completely different set of diseases are characterized by a
primary reduction in K1, the ultrafiltration coefficient. In this
case, the result is a fall in GFR, with or without changes in
plasma flow and the glomerular capillary pressure. The impor-
tance of this primary reduction in Kf is demonstrated in Figure
3, where the single nephron GFR and its determinants in an
acute model (puromycin nephrosis) are depicted [9]. This model
features massive proteinuria, fluid overload, hypoalbuminemia,
and other characteristics of the nephrotic syndrome. As is
shown in Figure 3, glomerular capillary pressures and flows
remain fairly normal. In contrast, however, Kf is markedly
reduced, and in consequence, both the single nephron and
whole kidney GFR values are significantly impaired [9]. A
similar reduction in K1 has been noted in a number of models of
glomerulonephritis [13, 17]. Though not amenable to clinical
Table 1. Renal and glomerular hemodynamic patterns
Abbreviations are: GFR, glomerular filtration rate; QA glomerular
capillary plasma flow rate; P0, glomerular capillary hydraulic pres-
sure; Kf, glomerular capillary ultrafiltration coefficient; increased,
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Fig. 2. Effects of systemic hypertension, uninephrectomy (UNX), and
low protein (LP) diet on urinary protein excretion (UpR0TV) in the
Spontaneously Hypertensive Rat (SHR) and the Wistar Kyoto rat
(WKY). Symbols are: (El) WKY; (•) SHR; (A) WKY/UNX; (0)
SHRIUNX; ( SHR/UNX/LP. Intact SHR rats show UPROTV values
only slightly higher than those in the intact WKY. UNX dramatically
increases UPR0TV in the SHR, while feeding a low protein diet
abolishes the detrimental effect of UNX. Adapted from Ref. 11 with
permission.
measurement, indirect studies using dextran modelling suggest
that a decrease in Kf contributes importantly to glomerular
dysfunction in patients with lupus nephritis [3], and probably
other glomerulonephritides as well.
Effects of hormonal mediators on glomerular function and
disease
A second major use of single nephron studies is to allow
definition of the glomerular hemodynamic effects of various
vasoactive hormones and other mediators in the normal kidney,
and delineation of their roles in the pathogenesis of glomerular
disease. Dozens of hormone receptors have been identified in
glomeruli [4], and in vivo studies have confirmed the ability of
most of these to significantly influence SNGFR and its deter-
minants. Though by no means comprehensive, a list of some of
the recognized mediators is found in Table 2 [4, 18].
Detailed discussion of the literature concerning effects of
these mediators is beyond the scope of this review, but consid-
eration of two examples [the venerable hormone, angiotensin II
(Ang II), and the relatively newly described hormone, endothe-
lin] is illustrative of the approaches used to identify the actions
of a vasoactive mediator, and its contribution to glomerular
hemodynamics in disease states. The hemodynamic actions of
angiotensin II (elevation of systemic pressure, predominant
constriction of the efferent arteriole and consequent elevation
of PGC, and reduction in the ultrafiltration coefficient, Kf) were
identified in the 1970's with development of micropuncture
methodology [191. Later in that decade and in the early 1980's,
the advent of the relatively nonspecific Ang II receptor antag-
onist saralasin, and then angiotensin converting enzyme (ACE)
inhibitors, allowed investigations into the role of this hormone
in mediation of glomerular disease. Studies showing reversal of
vasoconstriction in certain states (such as congestive heart
failure [20]), were followed by studies showing reduction of
blood pressure and efferent resistance, and elevation in Kr,
even in conditions not characterized by stimulation of the
renin-angiotensin system [7, 21]. More recently, specific AT1
angiotensin receptor antagonists have been used, and thus far
appear to reproduce many (though not all) of the characteristic
effects of ACE inhibition [22, 23]. Finally, though not yet
widely available, use of specific renin inhibitors and monoclonal
antibodies to Ang II are likely to provide further insight into
specific Ang 11-mediated effects in the setting of glomerular
disease.
Fairly quickly after its initial description in 1988 [24], endo-
thelin was noted to have profound effects on systemic and
intrarenal hemodynamics, including dose-related increases in
systemic blood pressure and renal vascular resistance, and
decreases in renal perfusion and filtration rates [25, 26]. Mi-
cropuncture studies in normal rats revealed that at a modestly
pressor dose, endothein infusion produced constriction in the
glomerular arterioles, efferent > afferent, as well as a reduction
in Kf and increase in GC [25]. Later, the development of
anti-endothelin antibodies and eventually, specific endothelin
receptor antagonists, has begun to allow elucidation of the role
of this potent vasoconstrictor in the setting of renal disease [27,
28].
Many other hormones have been implicated in control of
glomerular function (Table 2), though some of these are not yet
well studied in the setting of glomerular disease. Relatively
newly available antagonists of the kallikrein-kinin system [29,
30], endothelial-derived relaxing factor [31—33], and leuko-
trienes [34], just to name a few, are stimulating extensive
investigation into mechanisms of disease.
Ongoing investigations into the hemodynamic (and other)
effects of hormonal mediators, and their roles in renal disease
are to be anticipated. Newly discovered hormones will be
studied, and development of more specific and potent blocking
agents (monoclonal antibodies, enzyme inhibitors, competitive
antagonists, specific receptor antagonists) for each of these will
allow more specific implication of their individual roles.
Identification of therapeutic mechanisms
A third major use of single nephron studies has been to
identify mechanisms contributing to the therapeutic efficacy of
various interventions. Many of the dietary and pharmacologic
therapies which are in use, both clinically and experimentally,
exert glomerular microcirculatory effects which may, at least in
part, explain their beneficial effect. (It should be noted, of
course, that successful therapies are most likely multidimen-
sional in their mechanisms; indeed, for some of the most
successful, numerous mechanisms of protection have been
postulated). Again, this review will not be comprehensive, but
will highlight some of the more prominent hemodynamic effects
of commonly used clinical strategies.
Dietary protein restriction has been advocated for decades as
a method to control uremic symptoms and more recently, as a
strategy to slow the progression of renal disease [35]. The older
observations that limiting protein intake reduces both renal
blood flow and GFR have been expanded more recently using
micropuncture techniques. The hemodynamic consequences of
dietary protein restriction in progressive renal disease were
described by Hostetter et al [15] in the remnant kidney rat
model (Fig. 1). As described above, the primary hemodynamic








Table 2. Potential mediators in renal disease
Angiotensin II IGF-l
Prostaglandins/thromboxanes Catecholamines
Kinins Atrial natriuretic peptide
Endothelin Glucagon
Endothelial-denved relaxing factor Leukotrienes
Epidermal growth factor Adenosine
Histamine Insulin
Platelet-derived growth factor Parathyroid hormone
Serotonin Vasopressin
Dopamine Platelet activating factor
Institution of a low protein diet restores RA to the normal range
(Fig. 1), thereby controlling glomerular capillary hypertension.
Subsequent studies have confirmed this beneficial effect on
afferent arteriolar tone in other models, including experimental
diabetes [6] and hypertension [11].
Antihypertensive therapy has received serious attention in
recent years. A number of studies have confirmed that the
various antihypertensive drugs available to the clinician exert
very dissimilar effects on intraglomerular hemodynamics.
While many drugs are as yet unstudied, certain drugs have been
sufficiently studied to draw some conclusions as to their effects.
Most intensively studied have been the ACE inhibitors, which
almost universally lower blood pressure, efferent resistance,
and GC in models with glomerular hypertension, and increase
the glomerular capillary coefficient. Accordingly, a beneficial
hemodynamic effect (that is, control of glomerular capillary
hypertension), is obtained by both dietary protein restriction
and ACE inhibition, albeit by different mechanisms. The effects
of these two interventions on arteriolar resistance in experimen-
tal diabetes are illustrated in Figure 4, representing data from
two studies by Zatz and coworkers [6, 7]. Dietary protein
restriction acts to limit PGC by increasing RA, whereas ACE
inhibition accomplishes the same goal by lowering RE (Fig. 4)
[6, 7]. While the potential additive benefit of these two inter-
ventions has been little studied, preliminary evidence showing













Fig. 3. Glomerular hemodynamic parameters in Sham rats and in nephrotic rats injected with puromycin aminonucleoside (PA). During the acute
nephrotic phase (2 wks, U), values for the single nephron glomerular filtration rate (SNGFR) were markedly reduced in PA rats, as compared to
sham rats. There were no changes in the glomerular capillary plasma flow rate (QA) or glomerular transcapillary hydraulic pressure gradient (P).
The low SNGFR resulted from a significant decrement in the glomerular capillary ultrafiltration coefficient, Kf. During the recovery phase (8
weeks, 0), SNGFR was normalized, at the expense of glomerular hypertension; these changes were prevented with converting enzyme inhibitor
(CEI) therapy. * P < 0.05 vs. Sham; t P < 0.05 vs. PA. Adapted from data in Ref. 9 with permission.
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Fig. 4. Effects of a low protein diet or converting enzyme inhibition
(CE!) on afferent (RA) and efferent (RE) arteriolar resistances in
diabetic rats. Protein restriction induced afferent arteriolar vasocon-
striction, whereas CR1 resulted in predominant efferent arteriolar
vasodilation. Both responses lowered glomerular capillary pressure.
Adapted from data in Refs. 6 and 7 with permission.
inhibition in patients with renal disease [36] indirectly supports
such a mechanism as a contributor to clinical disease. Similarly,
the clinical observation of an additive antiproteinuric effect of
—60












FIg. 5. Effects of combination reserpine, hydralazine and diuretic
therapy on afferent (RA) and efferent (RE) arteriolar resistances in four
models of experimental renal disease: 5/6 nephrectomy (NX); desoxy-
corticosterone (DOCA)-salt hypertension; the Spontaneously Hyper-
tensive Rat with uninephrectomy (SHR/UNX); and early diabetes
mellitus (DM). This regimen lowers RE, and thereby P0 in some
models, but not in others. Adapted from data in Refs. 21, 38, 39 and 40
with permission.
the hemodynamic context in which other pathophysiologic
processes and therapeutic mechanisms are revealed.
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intrarenal heniodynamic disease patterns, to identify the ac-
tions of various vasoactive mediators and thereby allow corre-
lation with disease processes, and to explain the mechanisms
underlying interventions which benefit the kidney. Many other
uses of these techniques have provided insight into clinical
disease pathophysiology, including: studies examining the im-
portance of changes in tubuloglomerular feedback; the role of
changes in tubular reabsorption; and studies correlating func-
tion with morphologic changes and with in vitro studies. While
this review has concentrated on in vivo glomerular micropunc-
ture techniques, a number of other innovative techniques are
being used to approach these questions, including studies in
isolated perfused tubules, afferent and efferent arterioles, and
glomeruli. Accordingly, these studies will continue to provide
nonsteroidal anti-inflammatory drugs (which increase RA in
experimental animals) and ACE inhibition [37] may suggest a
similar effect with this combination regimen.
While the results of most (though not all) studies with ACE
inhibitors indicate efferent arteriolar relaxation and lowering of
PGC, less consistency is found in the available studies of other
antihypertensive regimens. An older antihypertensive regimen
which has been frequently used to control experimental hyper-
tension consists of reserpine, hydralazine, and hydrochlorothi-
azide. However, while this regimen routinely affords excellent
control of systemic hypertension, its effects on artenolar resis-
tances appear to vary among different experimental models [21,
22, 38—40], for reasons which remain to be elucidated. Some
examples of such studies are depicted in Figure 5. The afferent
arteriolar response to the reduction in renal perfusion pressure
usually consists of a fall in RA. In some models, including
uninephrectomized SHR rats [38] and very early (but not late)
diabetic rats [39], this regimen also lowers RE and, thereby GC,
whereas in other models, including remnant kidney [21, 22] and
mineralocorticoid-salt hypertensive [40] rats, there is no such
reduction in either RE or PGC, and consequently no ameliora-
tion of progressive renal injury.
Effects of other antihypertensive drugs are much less well
studied, Conflicting results have been found in the sparse
reports using calcium antagonists [41, 421. While these agents
frequently reduce RA (either directly, or in response to a
reduction in blood pressure), effects on RE and GC are vari-
able. These variable hemodynamic effects may explain, at least
in part, the similarly variable effect of these agents on clinical
proteinuria [41], as reducing proteinuria is consistent with
(though by no means diagnostic of) a reduction in glomerular
capillary pressure.
Summary and conclusions
The preceding article has illustrated a few of the many studies
utilizing single nephron micropuncture techniques to identify
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